3 results
Primary:to assess the glycemic effects of a single dose of OXM on the ambient glucose levels during a GGI assessmentto assess the insulinotropic effects of a single dose of OXM measured as a change in "*" during a GGI assessmentSecondary:…
Objectives of part A:- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after 5 days of dosing in people with Parkinson's disease- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after…
To examine the safety, tolerability, and pharmacokinetic profile of single ascending doses of AZ-009 compared to placebo (part B and C) or to Apo-Go (part A) in healthy volunteers being pretreated with domperidone and in patients with Parkinson…